| Angela Hustey, | |
|
3715 Panther Dr, Zanesville, OH 43701-7086 | |
| (740) 454-4490 | |
| Not Available |
| Full Name | Angela Hustey |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3715 Panther Dr, Zanesville, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003583139 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SP07327 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Angela Hustey, 7124 Eaglepoint Dr, Nashport, OH 43830-9325 Ph: () - | Angela Hustey, 3715 Panther Dr, Zanesville, OH 43701-7086 Ph: (740) 454-4490 |
News Archive
Unmarried patients with cancer are less likely to get potentially life-saving surgery or radiotherapy than their married counterparts, raising the concern that medical providers may be relying on stereotypes that discount sources of social support other than a current spouse.
Autosomal-dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders, affecting one in every 1,000 people and responsible for up to ten percent of patients on dialysis worldwide. The disease is characterized by the development of cysts that lead to progressive kidney failure and necessitate dialysis or a kidney transplant in most patients aged around fifty. Moreover, the persistent cyst growth causes high blood pressure and painful complications.
Researchers at the Lankenau Institute for Medical Research (LIMR) announced today that they have discovered an effective way to enlist the immune system to help chemotherapy destroy breast cancer cells. The work, led by LIMR researchers Alexander J. Muller and George C. Prendergast, is reported in the March 2005 edition of the leading international medical journal Nature Medicine.
VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.
› Verified 8 days ago
Alexis Hope Dalponte, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1701 Blue Ave, Zanesville, OH 43701 Phone: 740-453-0335 | |
Mrs. Vickye Lynn Lewis, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 711 Fess St, Zanesville, OH 43701 Phone: 740-453-0576 Fax: 740-453-3235 | |
Mrs. Courtney Graham Jones, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2809 Center Dr, Zanesville, OH 43701 Phone: 740-704-3015 | |
Mrs. Abbe Nicole Mumford, CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 205 N 7th St, Zanesville, OH 43701 Phone: 740-452-4518 | |
The Carr Center Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1035 Beverly Ave, Zanesville, OH 43701 Phone: 740-453-5417 Fax: 740-453-5480 | |
Rachel Sensabaugh, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1330 Newark Rd, Zanesville, OH 43701 Phone: 740-455-4176 Fax: 740-450-9225 |